Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Phase 2

Completed

Conditions: Esophagogastric Junction
Gastric Cancer
Gastric Adenocarcinoma

Interventions: Procedure: Surgery
Drug: Cisplatin
Drug: Mitomycin C
Drug: Sodium Thiosulfate

First Posted Date: 2017-03-28

Last Posted Date: 2024-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT03092518

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma
Locally Advanced
Unresectable

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2017-03-28

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT03093922

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 6 locations

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Lung Carcinomas, Non-Small-Cell
Non-small-cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Carcinoma，Non-Small-Cell Lung

Interventions: Drug: Pemetrexed
Drug: cemiplimab
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2017-03-23

Last Posted Date: 2024-06-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 712

Registration Number: NCT03088540

Locations: 🇺🇦
Clinical Study Site 2, Kyiv, Ukraine
🇹🇷
Clinical Study Site 3, İzmir, Turkey
🇧🇷
Clinical Study Site #3, São Paulo, Brazil

and more 9 locations

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Epacadostat
Drug: Pembrolizumab
Drug: Oxaliplatin
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cyclophosphamide
Drug: nab-Paclitaxel
Drug: Carboplatin
Drug: Paclitaxel
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Cisplatin
Drug: Investigator's choice of platinum agent

First Posted Date: 2017-03-21

Last Posted Date: 2022-09-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 70

Registration Number: NCT03085914

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 12 locations

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Phase 3

Withdrawn

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2017-03-15

Last Posted Date: 2018-02-19

Lead Sponsor: University of Louisville

Registration Number: NCT03081039

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

Phase 4

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: cisplatin
Drug: ifosfamide
Drug: gemcitabine
Drug: L-asparaginase
Drug: etoposide
Drug: dexamethasone

First Posted Date: 2017-03-07

Last Posted Date: 2018-06-11

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 50

Registration Number: NCT03071822

Locations: 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong

A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer

Phase 3

Recruiting

Conditions: Cervical Cancer
Lymphocyst
Radiation Therapy

Interventions: Radiation: Radiation Method B
Drug: Cisplatin
Radiation: Radiation Method A

First Posted Date: 2017-03-06

Last Posted Date: 2017-07-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 540

Registration Number: NCT03071289

Locations: 🇨🇳
Sun Yat-sen University Affiliated Foshan Hospital, Foshan, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
The First affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

and more 5 locations

IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: Intensity modulated radiotherapy
Drug: Cisplatin

First Posted Date: 2017-03-03

Last Posted Date: 2017-03-03

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 716

Registration Number: NCT03068936

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Phase 3

Recruiting

Conditions: Stage I Ovarian Choriocarcinoma
Stage I Testicular Embryonal Carcinoma AJCC v6 and v7
Stage I Testicular Seminoma AJCC v6 and v7
Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7
Stage II Testicular Yolk Sac Tumor AJCC v6 and v7
Stage III Ovarian Choriocarcinoma
Stage III Testicular Choriocarcinoma AJCC v6 and v7
Stage III Testicular Yolk Sac Tumor AJCC v6 and v7
Stage IV Ovarian Choriocarcinoma
Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7

Interventions: Procedure: Biopsy
Other: Best Practice
Procedure: Biospecimen Collection
Biological: Bleomycin Sulfate
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Other: Pharmacogenomic Study
Procedure: Pulmonary Function Test
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-03-01

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 2097

Registration Number: NCT03067181

Locations: 🇺🇸
Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
🇺🇸
Mercy San Juan Medical Center, Carmichael, California, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 614 locations

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Phase 3

Completed

Conditions: Small Cell Lung Cancer (SCLC)

Interventions: Biological: Pembrolizumab
Drug: Normal saline solution
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2017-02-28

Last Posted Date: 2022-10-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 453

Registration Number: NCT03066778

Locations: 🇨🇦
William Osler Health System (Brampton Civic Hospital) ( Site 0161), Brampton, Ontario, Canada
🇺🇸
Weinberg Cancer Institute at Franklin Square ( Site 1210), Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital ( Site 1203), Boston, Massachusetts, United States

and more 145 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy